Skip to main content

Immutep Health Care
Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
If you were already registered, log in here.

[ARTICLE] Telix Pharma buys Swiss blood cancer therapy unit

...

MediaBot

A news article has been posted about Immutep on the AFR. The article was published around , on 30 November 2020 at 3:24pm.

The Australian late-stage biotech has inked its second deal in a month – a Swiss-based biotech aiming to treat blood cancers and immunodeficiency diseases.

Read Article

IMM was $0.27 at the close of trade on 27 November 2020

Recent Articles about ASX:IMM
20-Dec Immutep MS therapy IMP761 found safe in initial Phase 1 trial data

multiplesclerosisnewstoday.com
18-Dec Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

uk.finance.yahoo.com
17-Dec Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761

menafn.com
17-Dec Immutep, Monash Reveal LAG-3 Binding to MHC Class II

miragenews.com
17-Dec Health Check: Clinical trials don’t sleigh down for the silly season

msn.com
17-Dec Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

msn.com
17-Dec Immutep Reveals Promising Data for IMP761 Trial

markets.businessinsider.com
17-Dec Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

markets.businessinsider.com
16-Dec Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

manilatimes.net
16-Dec Study Sheds Light on New Ways for Immunotherapy to Better Target Cancer

technologynetworks.com
Tracked

Find all articles about Immutep, including others on the AFR, on the media page.

If you were already registered, log in here.

If you were already registered, log in here.

If you were already registered, log in here.